A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
10/2002
10/17/2002	US20020150551 Protease surface treatment
10/17/2002	US20020150536 Nucleic acid ligands to integrins
10/17/2002	US20020150534 Tumor necrosis factor-gamma
10/17/2002	CA2446886A1 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
10/17/2002	CA2446462A1 Chimeric vaccines
10/17/2002	CA2443813A1 Method for identification of proteins from intracellular bacteria
10/17/2002	CA2443323A1 Nucleic acid vaccines for prevention of flavivirus infection
10/17/2002	CA2443293A1 Production of polyclonal monospecific antibodies against upar variants del4, del5 and del4+5, and the use thereof for diagnostic and therapeutical purposes
10/17/2002	CA2443275A1 Improved gene expression
10/17/2002	CA2443039A1 Artificial chromosomes comprising ehv sequences
10/17/2002	CA2442817A1 Implantation serine proteinases
10/17/2002	CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002	CA2442685A1 Estrogen receptor-related receptor alpha (err.alpha.) and cartilage formation
10/17/2002	CA2442386A1 Epitope sequences
10/17/2002	CA2442092A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
10/17/2002	CA2441628A1 Alpha-galactosidase as food-grade genetic marker
10/17/2002	CA2441442A1 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	CA2440219A1 Proteins, polynucleotides encoding them and methods of using the same
10/17/2002	CA2439111A1 Mucosal boosting following parenteral priming
10/17/2002	CA2435528A1 Novel polypeptides and nucleic acids encoded thereby
10/17/2002	CA2434456A1 Yeast genes that affect viral replication
10/17/2002	CA2429376A1 Mitogenic oxygenase regulators
10/16/2002	EP1249495A1 Murine DNase X, pharmaceuticals containing thereof and non-human mammal with modified DNase X-gene
10/16/2002	EP1248858A1 Antisense modulation of caspase 8 expression
10/16/2002	EP1248849A1 Obg3 globular head and uses thereof for decreasing body mass
10/16/2002	EP1248843A2 Nphs2 gene involved in the cortico-resistant neprhotic syndrome, protein encoded by said gene and diagnostic and therapeutic uses
10/16/2002	EP1248841A2 Genes differentially expressed in breast cancer
10/16/2002	EP1248835A2 Genetically modified fibroblast cell
10/16/2002	EP1248801A1 Human polynucleotides, polypeptides, and antibodies
10/16/2002	EP1248795A1 Antisense modulation of macrophage migration inhibitory factor expression
10/16/2002	EP1248794A1 Antisense modulation of smad7 expression
10/16/2002	EP1248793A1 Polynucleotides for inhibiting metastasis and tumor cell growth
10/16/2002	EP1248792A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression
10/16/2002	EP1248791A1 Antisense modulation of caspase 3 expression
10/16/2002	EP1248654A2 Intra-tumoral administration of il-12 encoding nucleic acid molecules
10/16/2002	EP1248653A2 Gene therapy to promote angiogenesis and/or the treatment of heart failure
10/16/2002	EP1248650A2 Improved dna vaccines for production-type animals
10/16/2002	EP1248646A2 Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another enteric pathogen
10/16/2002	EP1248634A1 Antisense modulation of mekk2 expression
10/16/2002	EP1248633A1 Antisense modulation of glycogen synthase kinase 3 beta expression
10/16/2002	EP1248517A2 Clonal propagation of primate offspring by embryo splitting
10/16/2002	EP1248516A2 38 human secreted proteins
10/16/2002	EP1206574A4 Guanidinium functionalized oligomers and methods
10/16/2002	EP1019417B1 Phospholipid analogue compounds
10/16/2002	EP0973794B1 Netrin receptors
10/16/2002	EP0941108B1 Wound healing and treatment of fibrosis
10/16/2002	EP0831919B1 Method for pharmaceutical delivery by gene therapy
10/16/2002	EP0637965B1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
10/16/2002	EP0619742B1 Transfection of lung via aerosolized transgene delivery
10/16/2002	CN1375004A Methods and compsotions for inhibiting the function of polynucleotide sequences
10/16/2002	CN1374869A Use of CASB 616 polypeptides and polynucleotides for cancer treatment
10/15/2002	US6465634 Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
10/15/2002	US6465631 To a nucleic acid encoding lipid a 4' kinase and to a method of producing lipid a 4' kinase recombinantly using same. the invention further relates to methods of producing 4' phosphorylated lipid a analogs using the recombinantly
10/15/2002	US6465627 DAX-1 protein, methods for production and use thereof
10/15/2002	US6465621 Polypeptides and polynucleotides of the gtp-binding protein family
10/15/2002	US6465438 Nucleic acid vaccination for parvoviral infections
10/15/2002	US6465422 Method for inhibiting tumor invasion or spreading in a subject
10/15/2002	US6465254 Nucleotide sequence (loxp site) where in the presence of recombinase cre, recombination with a wild-type loxp site can not occur, and recombination between two mutant loxp sites having the identical sequence occur; gene transfer
10/15/2002	US6465253 Vectors and methods for gene transfer to cells
10/15/2002	US6465248 Methods for producing and preparing cells for cell therapy
10/15/2002	US6465246 Oncogene- or virus-controlled expression systems
10/15/2002	US6465231 GSK3 polypeptides
10/15/2002	US6465211 Nucleic acids, vectors and transformed cells for making and using high affinity IP-3 binding polypeptides
10/15/2002	US6465007 Gene therapy using absorption enhancers or tight junction disrupters; transfection of a biologically active molecule by a cationic amphiphile: biologically active molecule complex or other lipid or viral or nonviral vectors; cystic fibrosis
10/15/2002	US6464998 Composition for the in vivo production of therapeutic products
10/15/2002	US6464984 Avian polynucleotide vaccine formula
10/15/2002	US6464980 MAGE-1 c-terminal immunogenic peptides
10/15/2002	US6464976 Selective anti-viral immuno-depletion (savid) immunoaffinity chromatographic material; viral coat protein of an adenovirus linked to a chromatographic support
10/15/2002	US6464973 Universal GM-CSF expressing bystander human K562 cell line
10/15/2002	US6464972 Recombinant poliovirus for the treatment of cancer
10/15/2002	US6464729 Reconstituted mineralized cartilage tissue
10/15/2002	US6463933 Bone marrow as a site for transplantation
10/10/2002	WO2002079517A1 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
10/10/2002	WO2002079478A2 Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders
10/10/2002	WO2002079470A1 Disease-specific promoter chimeras for gene expression
10/10/2002	WO2002079464A2 Viral vectors
10/10/2002	WO2002079404A2 Cytoskeleton-associated proteins
10/10/2002	WO2002079402A2 Method of inhibiting cancerous cell proliferation using ras mutants of gdp-bound conformation
10/10/2002	WO2002079401A2 Novel rgs9 protein binding interactions and methods of use thereof
10/10/2002	WO2002079390A2 $i(pesudomonas) avr and hop proteins, their encoding nucleic acids, and use thereof
10/10/2002	WO2002079388A2 Modulation of mhc class i antigen presentation
10/10/2002	WO2002079386A2 Isolated human ras-like proteins, nucleic and acid molecules encoding these human ras-like proteins, and uses thereof
10/10/2002	WO2002079385A2 Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
10/10/2002	WO2002079249A2 New polynucleotides and polypeptides of the ifn$g(a)-21 gene
10/10/2002	WO2002079238A2 Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis
10/10/2002	WO2002078863A1 Generation of pharmaceutical agent particles using focused acoustic energy
10/10/2002	WO2002078740A1 Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit ccr5-tropic hiv-1 infection and replication
10/10/2002	WO2002078733A1 Monocyte-specific particulate delivery vehicle
10/10/2002	WO2002078631A2 Improved conditionally replicating vectors for inhibiting viral infections
10/10/2002	WO2002078630A2 Tub 3'-variant
10/10/2002	WO2002078607A2 Mucin peptide with immunoenhancing properties
10/10/2002	WO2002078606A2 Thrombospondin-2 and uses thereof
10/10/2002	WO2002078526A2 Cancer-testis antigens
10/10/2002	WO2002078439A2 Prevascularized constructs for implantation to provide blood perfusion
10/10/2002	WO2002070552A8 POLYPEPTIDE FROM A HDM2 PROTEIN SPECIFIC MURINE Α/β T-CELL RECEPTORS, NUCLEIC ACIDS CODING FOR THE ABOVE AND USE THEREOF
10/10/2002	WO2002046373A8 Method of collecting placental stem cells
10/10/2002	WO2002026820A3 Immunomodulatory protein derived from the yaba monkey tumor virus
10/10/2002	WO2002016419A3 Progression suppressed gene 13 (psgen 13) and uses thereof
10/10/2002	WO2002008389A3 Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
10/10/2002	WO2002002599A3 HUMAN G PROTEIN-COUPLED RECEPTOR IGPcR17, AND USES THEROF

1 ... 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 ... 870